SNIPR Biome
PrivateLast Round
Series B
Aug 7, 2025
Total Funding Raised
$124.87M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SNIPR Biome operates in Healthcare & Life Sciences and is based in Copenhagen. Its latest recorded funding round was a Series B round in August 2025.
SNIPR Biome is a biotechnology company that develops CRISPR-based medicines designed to treat microbial diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SNIPR Biome Comparables
Compare SNIPR Biome with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Locus Biosciences | 88% | |
| Eligo Bioscience | 88% | |
| TechnoPhage | 77% |
For institutional investors. Book with your work email.
SNIPR Biome Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 7, 2025 | ||||
| Debt | Dec 9, 2024 | ||||
| Grant | Apr 22, 2024 | ||||
| Grant | May 27, 2021 | ||||
| Series A | Mar 11, 2019 | ||||
Seed | Jul 1, 2017 |
For institutional investors. Book with your work email.
SNIPR Biome Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lundbeck Foundation | Seed, Series A |
| EQT Life Sciences | Series A |
| CARB-X | Grant |
| Lundbeckfonden BioCapital | Series B |
| Gates Foundation | Grant |
| European Investment Bank Group | Debt |
| Cystic Fibrosis Foundation | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 62% MoM, reaching 1.5K.
- Sep 15, 2025
Developing a phage cocktail to treat Pseudomonas infections.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 12, 2026
SNIPR BIOME Aps develops engineered bacteriophages that selectively eliminate antibiotic-resistant E. coli, with SNIPR001 in a randomised Phase Ib/IIa trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics.
For institutional investors. Book with your work email.
SNIPR Biome Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SNIPR Biome's valuation, stock price, and market status.
Is SNIPR Biome a public or private company?
SNIPR Biome is a private company.
What is the current stock price of SNIPR Biome?
SNIPR Biome is a private company, so its shares have no public market price. Caplight tracks SNIPR Biome's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SNIPR Biome worth (valuation)?
Valuation information for SNIPR Biome is not publicly available.
Can I buy SNIPR Biome stock?
SNIPR Biome shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SNIPR Biome's last funding round?
SNIPR Biome's most recent funding round was Series B on August 7, 2025.
Who are the main investors in SNIPR Biome?
Key investors in SNIPR Biome include Lundbeck Foundation, EQT Life Sciences, CARB-X, Lundbeckfonden BioCapital, Gates Foundation.
Will SNIPR Biome IPO soon?
No public IPO plans have been announced for SNIPR Biome.
How can I track SNIPR Biome secondary market activity?
Caplight tracks bids, offers, and trades in SNIPR Biome's shares on secondary markets.